Bacteria Bacterium FDA Approval Marketing 
XTalks
JULY 28, 2021
Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.
Pharmaceutical Technology
OCTOBER 28, 2022
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 2, 2021
Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for Clostridium difficile infections. billion, but only included markets outside North America. diff infection.
XTalks
AUGUST 2, 2023
Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. The FDA approved the drug over a decade ago in September 2009.
XTalks
DECEMBER 24, 2020
Several saliva-based tests also received FDA approvals and authorizations, making sample collection easier and less invasive compared with traditional nasopharyngeal swabbing. Charpentier demonstrated that the CRISPR/Cas system functions to provide adaptive immunity against foreign DNA in prokaryotes such as bacteria and archaea.
Expert insights. Personalized for you.
89 
Let's personalize your content